International Development Grant
Improving Manufacturing Capacities for Vaccines in Latin America and the Caribbean
Project Number: CA-3-P011815001
Status: Operational
Country/Region: Unknown
Regional Focus:
Maximum Contribution: $15,000,000.00
Start Date: December 30, 2022
End Date: June 30, 2025
Duration: 2.5 years
Project Description
This project aims to decrease COVID-19 and other vaccine-preventable diseases related to mortality and morbidity of populations especially for those experiencing marginalization and/or vulnerability including women and children. This project accelerates the development of regional manufacturing of quality-assured safe and effective (Messenger ribonucleic acid (mRNA) vaccines to increase timely access for countries in the Americas. The project supports the Regional Platform to Advance the Manufacturing of COVID-19 Vaccines a multilateral collaboration between the Pan-American Health Organization (PAHO) the World Health Organization the Medicines Patent Pool and other partners. The project aligns with the global Access to COVID-19 Tools (ACT) Accelerator initiative to accelerate technology transfer for mRNA vaccine manufacturing capacities to low- and middle-income countries. This project supports partners from the regional hub-and-spoke institutions in Argentina and Brazil in vaccine development and production processes in the Americas region. Also it focuses on strengthening regional value chains to source the necessary components for a regional vaccine manufacturing value chain and to create an enabling environment for regional vaccine production by strengthening of national regulatory systems and relevant policies. Project activities include: (1) developing manufacturing capacities of mRNA and other technology platforms-based vaccines in selected institutions; (2) developing preclinical and clinical studies of mRNA candidate vaccines in selected institutions; (3) providing training in the development and manufacturing of vaccines through mRNA and other technological platforms; (4) facilitating inter-institutional articulation between Member States and other key partners to strengthen the vaccine value chain and enable sustainable projects for its development and production; (5) creating opportunities to enable the development of projects for regional
Expected Results
The expected outcomes of this project include: (1) increased supply of quality-assured vaccines for selected countries within the Americas with a focus on equitable access including marginalized populations and in vulnerable situations such as women and children; and (2) strengthened ecosystems conducive to quality-assured vaccine development and production in the Region of the Americas with a focus on equitable access including marginalized and vulnerable populations such as women and children.
Progress & Results Achieved
Results achieved as of December 2023 include: (1) implemented institutional development plans in 5 countries to improve their regulatory and multisectoral policy environment for vaccine production; (2) completed the evaluation of adverse reactions in pregnant women after COVID-19 vaccine administration using data from 11 countries; (3) issued policy recommendations to vaccine production stakeholders of Guyana following a technical cooperation visit; (4) completed 6 case studies on Argentina Brazil Chile Colombia Costa Rica and Mexico to explore opportunities to strengthen local manufacturing capacities especially in decision-making processes and gender approach; and (5) held 2 high-level meetings from the Advisory Committee of the Regional Platform and 2 technical dialogues related to local manufacturing.
Key Information
Executing Agency:
PAHO - Pan American Health Organization
Reporting Organization:
Global Affairs Canada
Program:
NGM Americas
Last Modified:
September 19, 2025
Development Classifications
DAC Sector:
Aid Type: Project-type interventions
Collaboration: Bilateral
Finance Type: Aid grant excluding debt reorganisation
Selection Mechanism:
Department-Initiated